Imunon (NASDAQ:IMNN – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $29.00 price objective on the stock.
Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Imunon in a research report on Thursday, December 19th.
Get Our Latest Analysis on Imunon
Imunon Stock Down 1.5 %
Institutional Investors Weigh In On Imunon
A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC increased its stake in Imunon, Inc. (NASDAQ:IMNN – Free Report) by 10.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the quarter. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. 4.47% of the stock is currently owned by hedge funds and other institutional investors.
Imunon Company Profile
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Featured Stories
- Five stocks we like better than Imunon
- Upcoming IPO Stock Lockup Period, Explained
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to Calculate Inflation Rate
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- The Risks of Owning Bonds
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.